Néstor Eduardo Llinás Quintero

Dr. Néstor Eduardo Llinás Quintero

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
HRHope Rugo
Hope Rugo
DCDavid W. Cescon
David W. Cescon
MRMark E. Robson
Mark E. Robson
SISeock-Ah Im
Seock-Ah Im
FDFlorence Dalenc
Florence Dalenc
ALANTONIO LLOMBART-CUSSAC
ANTONIO LLOMBART-CUSSAC
Purpose: Pembrolizumab plus olaparib versus pembrolizumab plus chemotherapy was evaluated as postinduction therapy for patients with PD-L1–unselected locally recurrent inoperable/metastatic triple-negative breast cancer (TNBC) who derived clinical benefit from first-line pembrolizumab plus platinum-based chemotherapy induction therapy. Patients and Methods: In this phase 2 study (NCT04191135), participants with previously untreated locally recurrent inoperable/metastatic TNBC received first-line pembrolizumab 200 mg once every 3 weeks plus platinum-based chemotherapy. Participants with complete/partial response or stable disease (per RECIST v1.1) were randomly assigned 1:1 to pembrolizumab 200 mg once every 3 weeks plus olaparib 300 mg twice a day or pembrolizumab plus chemotherapy. Progression-free survival (PFS) and overall survival (OS) were primary endpoints. Results: Of 460 participants receiving induction treatment, 271 were randomly assigned to postinduction therapy. The median PFS was 5.5 months in the pembrolizumab plus olaparib group versus 5.6 months in the pembrolizumab plus chemotherapy group [hazard ratio (HR), 0.98; 95% confidence interval (CI), 0.72–1.33; P = 0.4556]. The median OS was 25.1 versus 23.4 months, respectively (HR, 0.95; 95% CI, 0.64–1.40). In participants with tumor BRCA1/BRCA2 mutations (tBRCAm), HRs for PFS (HR, 0.70; 95% CI, 0.33–1.48) and OS (0.81; 95% CI, 0.28–2.37) favored pembrolizumab plus olaparib. Treatment-related adverse events occurred in 84.4% and 96.2% of participants receiving pembrolizumab plus olaparib and pembrolizumab plus chemotherapy, respectively. Conclusions: Although the primary endpoint was not met, postinduction pembrolizumab plus olaparib therapy resulted in similar PFS and OS compared with pembrolizumab plus chemotherapy in this setting. The positive trend for PFS and OS in participants with tBRCAm suggests a potential nonchemotherapy strategy for maintaining clinical benefit attained with first-line pembrolizumab plus chemotherapy induction treatment. No new safety signals were identified.

1 August 2021 in Cureus
Verified
Journal Article
Open access
GMGustavo Matute
Gustavo Matute
LBLinda Barcenas
Linda Barcenas
CBCarolina Bautista
Carolina Bautista
CRCarlos Alberto Restrepo Ramirez
Carlos Alberto Restrepo Ramirez
NQNéstor Eduardo Llinás Quintero
Néstor Eduardo Llinás Quintero
Tall cell carcinoma with reversed polarity (TCCRP) of the breast is a rare entity with low potential for malignancy that exhibits some morphological similarities to the tall cell variant of papillary thyroid carcinoma. Immunohistochemical and molecular studies help establish the mammary origin of this neoplasm. Here, we describe the case of a 63-year-old woman with a finding of a nodular lesion during a screening mammogram, whose morphological findings and immunohistochemical studies confirmed the diagnosis of papillary high cell carcinoma with the reverse polarity of the mammary gland.

30 August 2021 in Cureus
Verified
Journal Article
Open access
GMGustavo Matute
Gustavo Matute
JMJulieth Alexandra Franco Mira
Julieth Alexandra Franco Mira
ATAstrid Arroyave Toro
Astrid Arroyave Toro
FQFredy Alberto Quintero
Fredy Alberto Quintero
JBJorge Alberto Bernal
Jorge Alberto Bernal
NQNéstor Eduardo Llinás Quintero
Néstor Eduardo Llinás Quintero
Desmoplastic small round cell tumor (DSRCT) is a rare malignancy, of uncertain differentiation, which more commonly affects adolescents and young adult males; it usually has an intra-abdominal location. We describe the case of a 35-year-old male who presented initially with occasional abdominal pain, and subsequently with abdominal mass sensation, without any other associated symptoms. Imaging studies reported an intra-abdominal mass located in mesogastrium, right hypochondrium, and right lumbar region, without clear evidence of infiltration to secondary structures, but with clear peritoneal spread to greater omentum and pelvis. Definitive diagnosis of DSRCT is based on histologic and immunohistochemical findings. Standard treatment includes intensive neoadjuvant chemotherapy, surgical cytoreduction, and radiotherapy. Despite this multidisciplinary approach, DSRCT has a poor prognosis and a high mortality rate at five years.

6 January 2019 in Case Reports in Oncological Medicine
Verified
Journal Article
Open access
PDF file
NQNéstor Eduardo Llinás Quintero
Néstor Eduardo Llinás Quintero
ECEduardo Cabrera-Florez
Eduardo Cabrera-Florez
GMGustavo Mendoza-Fandiño
Gustavo Mendoza-Fandiño
GMGustavo Matute-Turizo
Gustavo Matute-Turizo
EVElsa M. Vasquez-Trespalacios
Elsa M. Vasquez-Trespalacios
LGLuis J. Gallón-Villegas
Luis J. Gallón-Villegas
We report a case of a 52-year-old female with a family history of pancreatic and colon cancers who presented with a right breast mass positive for high-grade medullar carcinoma with triple-negative biomolecular profile. Further workup was performed finding a left ovarian mass. The patient underwent laparotomy performing optimal cytoreduction on bilateral ovarian tumors; the pathology and immunohistochemistry confirmed bilateral ovary adenocarcinoma with positive peritoneal malignancy. Due to her synchronic breast and ovarian cancers, a genetic profile was performed detecting a new pathogenic variant in the BRCA2 gene: c.3606_3607del (p.Ser1203Cysfs). She was given chemotherapy with carboplatin and paclitaxel obtaining complete clinical response. Regarding her breast cancer, she had a right modified radical mastectomy and prophylactic left mastectomy obtaining complete clinical response. This case presents with an unusual subtype and difficult histologic diagnosis of a synchronic medullar breast cancer and ovary carcinoma associated with a new mutation of the BRCA2 gene.

3 August 2023 in Revista Colombiana de Hematología y Oncología
Verified
Journal Article
Open access
PDF file
MLMauricio Lema
Mauricio Lema
NQNéstor Eduardo Llinás Quintero
Néstor Eduardo Llinás Quintero
ABAndres Bravo-Gonzalez
Andres Bravo-Gonzalez
JHJuan Camilo Hernández
Juan Camilo Hernández
During the COVID-19 pandemic, regulatory approval or expanded indications were granted for several immune checkpoint inhibitors in cancer treatment in Colombia. However, for various reasons, the practicing medical community faced difficulties in accessing updated information on these new indications. Objective: to review the new approvals by the National Institute for Food and Drug Surveillance (INVIMA) for immune checkpoint inhibitors with approvals issued between March 2020 and May 2022. Methods: New indications for immune checkpoint inhibitors were searched on the INVIMA website and in media sources. For cost information, Circular 12 for regulated drugs or the reference prices from the Drug Price Information System (SISMED) for unregulated drugs were consulted. A brief literature review was conducted for each indication, with a focus on study design, primary outcomes, grade 3 or higher toxicities, and estimated costs in Colombia. Results: New therapeutic indications were found for ipilimumab (anti-CTLA4), nivolumab (anti-PD1), pembrolizumab (anti-PD1), atezolizumab (anti-PD-L1), durvalumab (anti-PD-L1), and avelumab (anti-PD-L1). Nine new indications were approved between March 2020 and May 2022. Pembrolizumab obtained four new indications, including for colorectal cancer with microsatellite instability or DNA mismatch repair deficiency, triple-negative breast cancer, esophageal cancer, and Hodgkin's lymphoma. The combination of atezolizumab and bevacizumab is indicated for advanced hepatocellular carcinoma. Ipilimumab plus nivolumab (with chemotherapy) is approved for metastatic non-small cell lung cancer. Durvalumab in combination with chemotherapy is indicated for extensive-stage small cell lung cancer. Avelumab is approved for maintenance therapy in advanced urothelial cancer and in combination with axitinib for metastatic renal cell carcinoma. The toxicities observed in the registration studies are consistent with the expected profile for this class of agents. Conclusion: The expansion of the number and scope of regulatory approvals for immune checkpoint inhibitors in Colombia presents an additional opportunity for the benefit of cancer patients.

30 November 2020 in Revista Colombiana de Cancerología
Verified
Journal Article
Closed access
PDF file
FMFernando Herazo Maya
Fernando Herazo Maya
RMRicardo Brugés Maya
Ricardo Brugés Maya
AUAna Lucia Hincapie Uribe
Ana Lucia Hincapie Uribe
ABAna María Carvajal Barrera
Ana María Carvajal Barrera
AOAylen Vanessa Ospina-Serrano
Aylen Vanessa Ospina-Serrano
RMRay Manneh
Ray Manneh
Bajo las nuevas condiciones generadas por la pandemia de COVID-19, los tratamientos para el cáncer de mama requieren algunas reorientaciones y cuidados que se exponen en este artículo. Se consideran aquí las tres fases de gravedad de la pandemia y los respectivos tratamientos que demandan en función de los lineamientos dictados por el Ministerio de Salud y Protección Social de Colombia. Se trata de un conjunto de referencias para orientar las terapias y tratamientos, inspiradas en las políticas de salud regionales, nacionales e institucionales.